{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:43:02Z","timestamp":1792212182157,"version":"4.4.0"},"reference-count":31,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,10,15]]},"DOI":"10.1248\/bpb.b26-00269","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:11:03Z","timestamp":1792015863000},"page":"1667-1675","source":"Crossref","is-referenced-by-count":0,"title":["Radio-Biological Enhancement of an Interleukin-6 Receptor Antibody by the &lt;i&gt;\u03b2&lt;\/i&gt;-Particle-Emitting Radionuclide Iodine-131 in Multiple Myeloma"],"prefix":"10.1248","volume":"49","author":[{"given":"Hiroki","family":"Goto","sequence":"first","affiliation":[{"name":"Division of Radioisotope and Tumor Pathobiology, Institute of Resource Development and Analysis, Kumamoto University, 2\u20132\u20131 Honjo, Chuo-ku, Kumamoto 860\u20130811, Japan"},{"name":"Radioisotope Center, Institute of Resource Development and Analysis, Kumamoto University, 2\u20132\u20131 Honjo, Chuo-ku, Kumamoto 860\u20130811, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Ueda","sequence":"first","affiliation":[{"name":"Division of Radioisotope and Tumor Pathobiology, Institute of Resource Development and Analysis, Kumamoto University, 2\u20132\u20131 Honjo, Chuo-ku, Kumamoto 860\u20130811, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Takano","sequence":"additional","affiliation":[{"name":"Division of Radioisotope and Tumor Pathobiology, Institute of Resource Development and Analysis, Kumamoto University, 2\u20132\u20131 Honjo, Chuo-ku, Kumamoto 860\u20130811, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prin","family":"Sungwan","sequence":"additional","affiliation":[{"name":"Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 2\u20132\u20131 Honjo, Chuo-ku, Kumamoto 860\u20130811, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshioki","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"Radioisotope Center, Institute of Resource Development and Analysis, Kumamoto University, 2\u20132\u20131 Honjo, Chuo-ku, Kumamoto 860\u20130811, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Radiological Sciences, School of Health Sciences, Fukushima Medical University, 10\u20136 Sakaemachi, Fukushima 960\u20138516, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[{"name":"Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 2\u20132\u20131 Honjo, Chuo-ku, Kumamoto 860\u20130811, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN. Diagnosis and management of multiple myeloma: a review. <i>JAMA<\/i>, <b>327<\/b>, 464\u2013477 (2022).","DOI":"10.1001\/jama.2022.0003"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Garfall AL. New biological therapies for multiple myeloma. <i>Annu. Rev. Med.<\/i>, <b>75<\/b>, 13\u201329 (2024).","DOI":"10.1146\/annurev-med-050522-033815"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. <i>Front. Endocrinol.<\/i>, <b>9<\/b>, 788 (2019).","DOI":"10.3389\/fendo.2018.00788"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. <i>Int. Immunopharmacol.<\/i>, <b>5<\/b>, 1731\u20131740 (2005).","DOI":"10.1016\/j.intimp.2005.05.010"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller J. Targeting IL-6 <i>trans<\/i>-signalling: past, present and future prospects. <i>Nat. Rev. Immunol.<\/i>, <b>23<\/b>, 666\u2013681 (2023).","DOI":"10.1038\/s41577-023-00856-y"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Lan SH, Lai CC, Huang HT, Chang SP, Lu LC, Hsueh PR. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. <i>Int. J. Antimicrob. Agents<\/i>, <b>56<\/b>, 106103 (2020).","DOI":"10.1016\/j.ijantimicag.2020.106103"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Goto H, Kudo E, Kariya R, Taura M, Katano H, Okada S. Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma. <i>J. Cancer Res. Clin. Oncol.<\/i>, <b>141<\/b>, 465\u2013474 (2015).","DOI":"10.1007\/s00432-014-1842-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Parisi S, Ditto MC, Ghellere F, Panaro S, Piccione F, Borrelli R, Fusaro E. Update on tocilizumab in rheumatoid arthritis: a narrative review. <i>Front. Immunol.<\/i>, <b>16<\/b>, 1470488 (2025).","DOI":"10.3389\/fimmu.2025.1470488"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A, Tsunasawa S, Sakiyama F, Matsui H, Takahara Y, Taniguchi T, Kishimoto T. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. <i>Nature<\/i>, <b>324<\/b>, 73\u201376 (1986).","DOI":"10.1038\/324073a0"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T. Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas. <i>Nature<\/i>, <b>332<\/b>, 83\u201385 (1988).","DOI":"10.1038\/332083a0"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A, Dessoly J, Sciaini AK, Benbunan M, Chomienne C, Fermand JP, Marolleau JP, Larghero J. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. <i>Leukemia<\/i>, <b>21<\/b>, 158\u2013163 (2007).","DOI":"10.1038\/sj.leu.2404466"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Das R, Strowig T, Verma R, Koduru S, Hafemann A, Hopf S, Kocoglu MH, Borsotti C, Zhang L, Branagan A, Eynon E, Manz MG, Flavell RA, Dhodapkar MV. Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. <i>Nat. Med.<\/i>, <b>22<\/b>, 1351\u20131357 (2016).","DOI":"10.1038\/nm.4202"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Chatterjee M, Honemann D, Lentzsch S, Bommert K, Sers C, Herrmann P, Mathas S, Dorken B, Bargou RC. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6\/gp130\/STAT3 pathway. <i>Blood<\/i>, <b>100<\/b>, 3311\u20133318 (2002).","DOI":"10.1182\/blood-2002-01-0102"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Goto H, Shiraishi Y, Okada S. Continuing progress in radioimmunotherapy for hematologic malignancies. <i>Blood Rev.<\/i>, <b>69<\/b>, 101250 (2025).","DOI":"10.1016\/j.blre.2024.101250"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Goldsmith SJ. Targeted radionuclide therapy: a historical and personal review. <i>Semin. Nucl. Med.<\/i>, <b>50<\/b>, 87\u201397 (2020).","DOI":"10.1053\/j.semnuclmed.2019.07.006"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Goto H, Shiraishi Y, Okada S. Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin\u2019s lymphoma. <i>Explor. Target. Antitumor Ther.<\/i>, <b>5<\/b>, 208\u2013224 (2024).","DOI":"10.37349\/etat.2024.00213"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Matthews DC, Martin PJ, Nourigat C, Appelbaum FR, Fisher DR, Bernstein ID. Marrow ablative and immunosuppressive effects of <sup>131<\/sup>I-anti-CD45 antibody in congenic and H2-mismatched murine transplant models. <i>Blood<\/i>, <b>93<\/b>, 737\u2013745 (1999).","DOI":"10.1182\/blood.V93.2.737.402k21_737_745"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Ono A, Hattori S, Kariya R, Iwanaga S, Taura M, Harada H, Suzu S, Okada S. Comparative study of human hematopoietic cell engraftment into BALB\/c and C57BL\/6 strain of rag-2\/jak3 double-deficient mice. <i>BioMed Res. Int.<\/i>, <b>2011<\/b>, 539748 (2011).","DOI":"10.1155\/2011\/539748"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Goto H, Kariya R, Matsuda K, Kudo E, Katano H, Okada S. A potential role of the NOD genetic background in mouse peritoneal macrophages for the development of primary effusion lymphoma. <i>Leuk. Res.<\/i>, <b>42<\/b>, 37\u201342 (2016).","DOI":"10.1016\/j.leukres.2016.01.011"},{"key":"20","unstructured":"20) Endo K, Kamma H, Ogata T. Radiolocalization of xenografted human lung cancer with monoclonal antibody 8 in nude mice. <i>Cancer Res.<\/i>, <b>47<\/b>, 5427\u20135432 (1987). \u2039https:\/\/aacrjournals.org\/cancerres\/article\/47\/20\/5427\/491765\/Radiolocalization-of-Xenografted-Human-Lung-Cancer\u203a."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Gozzetti A, Ciofini S, Sicuranza A, Pacelli P, Raspadori D, Cencini E, Tocci D, Bocchia M. Drug resistance and minimal residual disease in multiple myeloma. <i>Cancer Drug Resist.<\/i>, <b>5<\/b>, 171\u2013183 (2022).","DOI":"10.20517\/cdr.2021.116"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Dima D, Jiang D, Singh DJ, Hasipek M, Shah HS, Ullah F, Khouri J, Maciejewski JP, Jha BK. Multiple myeloma therapy: emerging trends and challenges. <i>Cancers<\/i>, <b>14<\/b>, 4082 (2022).","DOI":"10.3390\/cancers14174082"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Ohguchi Y, Ajiro M, Ogiya D, Masuda T, Kawano Y, Usuki S, Koga T, Hino SD, Harada T, Takahashi S, Okada S, Yasunaga JI, Sashida G, Ohtsuki S, Nakao M, Minami T, Yoshimi A, Ohguchi H. IL-6-driven POU2AF1 and ELL2 are key regulators of multiple myeloma-distinct transcriptional and splicing programs. <i>Blood Adv.<\/i>, <b>10<\/b>, 4049\u20134066 (2026).","DOI":"10.1182\/bloodadvances.2025018710"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Grebenciucova E, VanHaerents S. Interleukin 6: at the interface of human health and disease. <i>Front. Immunol.<\/i>, <b>14<\/b>, 1255533 (2023).","DOI":"10.3389\/fimmu.2023.1255533"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Bisht K, Walker B, Kumar SK, Spicka I, Moreau P, Martin T, Costa LJ, Richter J, Fukao T, Mace S, van de Velde H. Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. <i>Expert Rev. Hematol.<\/i>, <b>14<\/b>, 1099\u20131114 (2021).","DOI":"10.1080\/17474086.2021.1983427"},{"key":"26","unstructured":"26) Jernberg H, Pettersson M, Kishimoto T, Nilsson K. Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines. <i>Leukemia<\/i>, <b>5<\/b>, 255\u2013265 (1991)."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Al Shoyaib A, Archie SR, Karamyan VT. Intraperitoneal route of drug administration: should it be used in experimental animal studies? <i>Pharm. Res.<\/i>, <b>37<\/b>, 12 (2020).","DOI":"10.1007\/s11095-019-2745-x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Goto H, Takano M, Shiraishi Y, Luanpitpong S. Immuno-positron emission tomography as a new frontier in imaging hematologic malignancies. <i>World J. Clin. Oncol.<\/i>, <b>16<\/b>, 108585 (2025).","DOI":"10.5306\/wjco.v16.i9.108585"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Bosma GC, Fried M, Custer RP, Carroll A, Gibson DM, Bosma MJ. Evidence of functional lymphocytes in some (leaky) scid mice. <i>J. Exp. Med.<\/i>, <b>167<\/b>, 1016\u20131033 (1988).","DOI":"10.1084\/jem.167.3.1016"},{"key":"30","unstructured":"30) Shiraishi Y, Gotoh K, Towata T, Shimasaki T, Suzu S, Kojima A, Okada S. Therapeutic effects of gamma-irradiation in a primary effusion lymphoma mouse model. <i>Exp. Ther. Med.<\/i>, <b>1<\/b>, 79\u201384 (2010). \u2039https:\/\/www.spandidos-publications.com\/10.3892\/etm_00000014\u203a."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Camacho X, Cabrera M, Perroni C, Tassano M, Fernandez M, Oddone N, Riva E, Gambini JP, Cabral P. Theranostic potential of [177Lu]Lu-DOTA-tocilizumab in multiple myeloma: a preclinical evaluation. <i>Anticancer Agents Med. Chem.<\/i>, <b>26<\/b>, 1573\u20131583 (2026).","DOI":"10.2174\/0118715206406408251125050709"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/10\/49_b26-00269\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:21:55Z","timestamp":1792210915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/10\/49_b26-00269\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00269","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"article-number":"b26-00269"}}